Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group


Ryan Allway

December 2nd, 2020

Psychedelics


Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (“Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the Conservative Drug Policy Reform Group (CDPRG).

The Company is also pleased to announce that David King, director of research for CDPRG, has joined the Havn Life advisory board. King has co-authored several CDPRG white papers including ‘The UK Review of Medicinal Cannabis: The Needs of a Nation’ and ‘The Medicinal Use of Psilocybin: A call for reform.’ This year, King received the Dr Abbas Khan Medal by King’s College London for ‘outstanding humanitarian contributions to the service of society’.

He is also a founder of the Breaking Convention, Europe’s largest academic conference on psychedelic drug research, and was a founding director of the Breaking Convention charity from 2010 to 2019.

The CDPRG is a UK-based organization that assembles evidence from across the fields of medicine, law-enforcement, economics, ethics, criminology and human rights, for the benefit of drug policy-making. This year the CDPRG launched a campaign to reschedule psilocybin in the UK as part of their mission to provide greater access for research and medicinal purposes. Havn Life will commission 250 hours of work from CDPRG’s researchers.

“Being a part of the CDPRG global network of scientists allows us to utilize multidisciplinary expertise to develop psilocybin protocols that can have global impact,” says Tim Moore, Havn Life CEO. “Collaboration across fields allows us to move the needle. We are building a strong foundation of knowledge to develop a safe and reliable supply of naturally-derived psychedelic compounds for research”.

“As the clinical trial evidence for psychedelic therapies grows, it becomes increasingly clear that these interventions are safe, well-tolerated, and have the potential to change lives for the better, sometimes after only a single session,” says King. “We do not yet know what the real-world impact of these therapies will be, but there are good reasons to believe that we will be better equipped to treat some of the most difficult and burdensome conditions of the modern age, for which new approaches are desperately needed.”

King completed his undergraduate degree in medical anthropology in 2011, with a research thesis on beliefs and attitudes to health, illness and medicine among cannabis-using populations. He has also worked as a researcher at the Beckley Foundation and in immunology at the National University of Singapore. King was the founding President of both the award-winning Psychedelics Society at the University of Kent and the Society for Psychedelic Studies at King’s College London.

King first met Havn Life Chief Psychedelic Officer Dr. Ivan Casselman when they both were students together at the School of Anthropology and Conservation, University of Kent, over ten years ago.

“I am delighted to be working with Dr. Casselman and the other members of the Havn Life team as they move from strength to strength,” King adds. “Their collective experience, acumen and energy is remarkable and I anticipate the group accomplishing a great deal in the years ahead.”

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading